Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.

van Leenders GJLH, Kweldam CF, Hollemans E, Kümmerlin IP, Nieboer D, Verhoef EI, Remmers S, Incrocci L, Bangma CH, van der Kwast TH, Roobol MJ.

Eur Urol. 2019 Aug 19. pii: S0302-2838(19)30612-8. doi: 10.1016/j.eururo.2019.07.051. [Epub ahead of print]

PMID:
31439369
2.

Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.

Kweldam CF, Kümmerlin IP, Nieboer D, Steyerberg EW, Bangma CH, Incrocci L, van der Kwast TH, Roobol MJ, van Leenders GJ.

Mod Pathol. 2017 Aug;30(8):1126-1132. doi: 10.1038/modpathol.2017.29. Epub 2017 May 19.

3.

Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes.

Shah RB, Nguyen JK, Przybycin CG, Reynolds JP, Cox R, Myles J, Klein E, McKenney JK.

Histopathology. 2019 Sep;75(3):346-353. doi: 10.1111/his.13878. Epub 2019 Jul 2.

PMID:
31012493
4.

Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.

Roobol MJ, Verbeek JFM, van der Kwast T, Kümmerlin IP, Kweldam CF, van Leenders GJLH.

Eur Urol. 2017 Jul;72(1):45-51. doi: 10.1016/j.eururo.2017.01.033. Epub 2017 Feb 2.

PMID:
28162815
5.

Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.

Kweldam CF, Kümmerlin IP, Nieboer D, Verhoef EI, Steyerberg EW, van der Kwast TH, Roobol MJ, van Leenders GJ.

Mod Pathol. 2016 Jun;29(6):630-6. doi: 10.1038/modpathol.2016.49. Epub 2016 Mar 4.

6.

The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance.

Kato M, Hirakawa A, Kobayashi Y Ms, Yamamoto A, Ishida R, Sano T, Kimura T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Yamamoto T, Hattori R, Gotoh M, Tsuzuki T.

Prostate. 2019 Jul;79(10):1065-1070. doi: 10.1002/pros.23818. Epub 2019 Apr 26.

PMID:
31025722
7.

GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.

Jeyapala R, Savio AJ, Olkhov-Mitsel E, Kamdar S, Zhao F, Cuizon C, Liu RSC, Zlotta A, Fleshner N, van der Kwast T, Bapat B.

Eur Urol Oncol. 2019 May;2(3):231-238. doi: 10.1016/j.euo.2018.08.003. Epub 2018 Sep 1.

PMID:
31200836
8.

Metastatic potential to regional lymph nodes with Gleason score ≤7, including tertiary pattern 5, at radical prostatectomy.

Diolombi ML, Epstein JI.

BJU Int. 2017 Jun;119(6):872-878. doi: 10.1111/bju.13623. Epub 2016 Sep 2.

9.

Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.

Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, Ghabili K, Agostino J, Macura KJ, Carter HB, Schaeffer EM, Partin AW, Sokoll LJ, Ross AE.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):228-233. doi: 10.1038/pcan.2016.72. Epub 2017 Jan 24.

10.

Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.

Viers BR, Sukov WR, Gettman MT, Rangel LJ, Bergstralh EJ, Frank I, Tollefson MK, Thompson RH, Boorjian SA, Karnes RJ.

Eur Urol. 2014 Dec;66(6):1116-24. doi: 10.1016/j.eururo.2014.07.004. Epub 2014 Jul 19.

PMID:
25052213
11.

A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.

McKiernan J, Donovan MJ, Margolis E, Partin A, Carter B, Brown G, Torkler P, Noerholm M, Skog J, Shore N, Andriole G, Thompson I, Carroll P.

Eur Urol. 2018 Dec;74(6):731-738. doi: 10.1016/j.eururo.2018.08.019. Epub 2018 Sep 17.

12.

Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies.

Shah RB, Magi-Galluzzi C, Han B, Zhou M.

Am J Surg Pathol. 2010 Apr;34(4):470-7. doi: 10.1097/PAS.0b013e3181cfc44b.

PMID:
20182345
13.

Grade Group Underestimation in Prostate Biopsy: Predictive Factors and Outcomes in Candidates for Active Surveillance.

Audenet F, Rozet F, Resche-Rigon M, Bernard R, Ingels A, Prapotnich D, Sanchez-Salas R, Galiano M, Barret E, Cathelineau X.

Clin Genitourin Cancer. 2017 Dec;15(6):e907-e913. doi: 10.1016/j.clgc.2017.04.024. Epub 2017 Apr 26.

PMID:
28522288
14.

Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma.

Kweldam CF, Kümmerlin IP, Nieboer D, Verhoef EI, Steyerberg EW, Incrocci L, Bangma CH, van der Kwast TH, Roobol MJ, van Leenders GJ.

Eur J Cancer. 2016 Oct;66:26-33. doi: 10.1016/j.ejca.2016.07.012. Epub 2016 Aug 11.

PMID:
27522247
15.

Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.

Khani F, Epstein JI.

Am J Surg Pathol. 2015 Oct;39(10):1383-9. doi: 10.1097/PAS.0000000000000465.

PMID:
26076065
16.

ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia.

Han B, Suleman K, Wang L, Siddiqui J, Sercia L, Magi-Galluzzi C, Palanisamy N, Chinnaiyan AM, Zhou M, Shah RB.

Am J Surg Pathol. 2010 Apr;34(4):478-85. doi: 10.1097/PAS.0b013e3181d6827b.

PMID:
20220513
17.

The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two-Center Validation Study.

Dell'Oglio P, Karnes RJ, Gandaglia G, Fossati N, Stabile A, Moschini M, Cucchiara V, Zaffuto E, Karakiewicz PI, Suardi N, Montorsi F, Briganti A.

Prostate. 2017 Feb;77(3):263-273. doi: 10.1002/pros.23265. Epub 2016 Oct 18.

PMID:
27753114
18.

Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.

Wissing M, Brimo F, Chevalier S, Scarlata E, McKercher G, O'Flaherty A, Aprikian S, Thibodeau V, Saad F, Carmel M, Lacombe L, Têtu B, Ekindi-Ndongo N, Latour M, Trudel D, Aprikian A.

BJU Int. 2019 Apr;123(4):624-631. doi: 10.1111/bju.14512. Epub 2018 Sep 11.

PMID:
30113732
19.

Multiparametric MRI prior to radical prostatectomy identifies intraductal and cribriform growth patterns in prostate cancer.

Tonttila PP, Ahtikoski A, Kuisma M, Pääkkö E, Hirvikoski P, Vaarala MH.

BJU Int. 2019 May 18. doi: 10.1111/bju.14812. [Epub ahead of print]

PMID:
31102571
20.

Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis.

Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Helleman J, Roobol MJ, van Leenders GJLH.

Mod Pathol. 2019 Jan;32(1):139-146. doi: 10.1038/s41379-018-0157-9. Epub 2018 Oct 22.

Supplemental Content

Support Center